{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:31:56Z","timestamp":1790818316588,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001610","name":"Falk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.eclinm.2020.100271","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T03:07:02Z","timestamp":1580785622000},"page":"100271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials"],"prefix":"10.1016","volume":"20","author":[{"given":"Ole Haagen","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Steenholdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Bogh","family":"Juhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2020.100271_bib0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/M18-3060","article-title":"Biosimilars for management of Crohn disease","volume":"170","author":"Nielsen","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel targeted therapies for inflammatory bowel disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.eclinm.2020.100271_bib0003","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pharmthera.2018.07.003","article-title":"Targeting JAK-STAT signal transduction in IBD","volume":"192","author":"Soendergaard","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0006","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40262-015-0316-9","article-title":"Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease","volume":"55","author":"Coskun","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eclinm.2020.100271_bib0007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-86-2-199","article-title":"Methotrexate","volume":"86","author":"Weinstein","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0008","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jcph.2","article-title":"Recent advances using immunomodulators for inflammatory bowel disease","volume":"53","author":"Nielsen","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0009","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease","volume":"110","author":"Kozarek","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0011","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0012","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis","volume":"150","author":"Carbonnel","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0013","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2018.06.046","article-title":"Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis","volume":"155","author":"Herfarth","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0014","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National cooperative Crohn\u2019s disease study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2020.100271_bib0016","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2020.100271_bib0018","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn\u2019s disease: a prospective multicentre study. Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2020.100271_bib0019","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.eclinm.2020.100271_bib0020","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M","article-title":"A simple method for converting an odds ratio to effect size for use in meta-analysis","volume":"19","author":"Chinn","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0021","first-page":"1724","article-title":"Methotrexate in Crohn\u2019s disease: results of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s study group investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0023","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. North American Crohn\u2019s study group investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0024","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0025","first-page":"2203","article-title":"Methotrexate in chronic active Crohn\u2019s disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","article-title":"Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn\u2019s disease: a controlled pilot study","volume":"18","author":"Schroder","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"suppl. 3","key":"10.1016\/j.eclinm.2020.100271_bib0027","first-page":"A75","article-title":"Low-dosage weekly methotrexate therapy in remission maintenance in ulcerative colitis","volume":"39","author":"Onuk","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2020.100271_bib0028","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0029","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/BF01296109","article-title":"Low-dose oral methotrexate in refractory inflammatory bowel disease","volume":"38","author":"Baron","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.eclinm.2020.100271_bib0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease","volume":"110","author":"Kozarek","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2036.2001.00908.x","article-title":"Efficacy of parenteral methotrexate in refractory Crohn\u2019s disease","volume":"15","author":"Chong","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0032","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MCG.0b013e31802e6875","article-title":"Long-term methotrexate for Crohn\u2019s disease: safety and efficacy in clinical practice","volume":"42","author":"Domenech","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0033","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/MEG.0b013e3283556db5","article-title":"Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience","volume":"24","author":"Gonzalez-Lama","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0034","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ibd.21166","article-title":"Methotrexate for maintenance of remission in chronic active Crohn\u2019s disease: long-term single-center experience and meta-analysis of observational studies","volume":"16","author":"Hausmann","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.0953-0673.1996.00309.x","article-title":"Methotrexate for the treatment of refractory Crohn\u2019s disease","volume":"10","author":"Lemann","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0036","first-page":"1730","article-title":"Methotrexate in Crohn\u2019s disease: long-term efficacy and toxicity","volume":"95","author":"Lemann","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0037","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1440-1746.2007.05006.x","article-title":"A single center experience of methotrexate in the treatment of Crohn\u2019s disease and ulcerative colitis: a case for subcutaneous administration","volume":"23","author":"Nathan","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0038","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cgh.2012.12.026","article-title":"Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn\u2019s disease","volume":"11","author":"Seinen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0039","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2036.2011.04925.x","article-title":"Efficacy and tolerability of methotrexate therapy for refractory Crohn\u2019s disease: a large single-centre experience","volume":"35","author":"Suares","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0040","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2036.2009.04073.x","article-title":"Efficacy of methotrexate in Crohn\u2019s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine \/mercaptopurine","volume":"30","author":"Wahed","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0041","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0042","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.cgh.2019.02.043","article-title":"Canadian association of gastroenterology clinical practice guideline for the management of luminal Crohn\u2019s disease","volume":"17","author":"Panaccione","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0043","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/MIB.0b013e31828133e8","article-title":"Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the veterans affairs health care system","volume":"19","author":"Khan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0044","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0045","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1046\/j.1365-2036.2002.01340.x","article-title":"Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission","volume":"16","author":"Paoluzi","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0046","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2013how does it really work","volume":"6","author":"Chan","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0047","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2020.100271_bib0048","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.gastro.2014.08.003","article-title":"Converging goals of treatment of inflammatory bowel disease from clinical trials and practice","volume":"148","author":"Levesque","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0049","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0050","first-page":"S576","article-title":"Patient reported outcome measures (PROMs) in inflammatory bowel disease: new data","volume":"11","author":"Bojic","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0051","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cgh.2018.01.032","article-title":"PROMises made, PROMises to be kept: patient-Reported outcome measures in inflammatory bowel diseases","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0052","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2036.2010.04569.x","article-title":"Mucosal healing with methotrexate in Crohn\u2019s disease: a prospective comparative study with azathioprine and infliximab","volume":"33","author":"Laharie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0053","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000482007","article-title":"Efficacy, safety and mucosal healing of methotrexate in a large longitudinal cohort of inflammatory bowel disease patients","volume":"96","author":"Rouiller-Braunschweig","year":"2017","journal-title":"Digestion"},{"key":"10.1016\/j.eclinm.2020.100271_bib0054","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ibd.21015","article-title":"Does methotrexate induce mucosal healing in Crohn\u2019s disease?","volume":"16","author":"Manosa","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn\u2019s disease: a randomised, investigator-blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0056","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1097\/MIB.0000000000000780","article-title":"Preoperative use of methotrexate and the risk of early postoperative complications in patients with inflammatory bowel disease","volume":"22","author":"Afzali","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0057","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1365-2036.2003.01790.x","article-title":"Fistula response to methotrexate in Crohn\u2019s disease: a case series","volume":"18","author":"Mahadevan","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0058","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00042737-200409000-00018","article-title":"Experience with the use of low-dose methotrexate for inflammatory bowel disease","volume":"16","author":"Soon","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0059","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1038\/ctg.2017.33","article-title":"Fistulizing Crohn\u2019s disease","volume":"8","author":"Scharl","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0060","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","article-title":"AGA technical review on perianal Crohn\u2019s disease","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100271_bib0061","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/07853890903559724","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management","volume":"42","author":"Larsen","year":"2010","journal-title":"Ann Med"},{"key":"10.1016\/j.eclinm.2020.100271_bib0062","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000957.pub2","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2020.100271_bib0063","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0064","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.cgh.2019.03.005","article-title":"Mortality associated with development of squamous cell cancer in patients with inflammatory bowel disease receiving treatment with thiopurines","volume":"17","author":"Khan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0065","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2020.100271_bib0066","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2020.100271_bib0067","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s10620-018-5422-8","article-title":"Higher mucosal healing with tumor necrosis factor inhibitors in combination with thiopurines compared to methotrexate in Crohn\u2019s disease","volume":"64","author":"Vasudevan","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.eclinm.2020.100271_bib0068","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/ecco-jcc\/jjz020","article-title":"Low-dose methotrexate has similar outcomes to high-dose methotrexate in combination with anti-TNF therapy in inflammatory bowel diseases","volume":"13","author":"Borren","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0069","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eclinm.2020.100271_bib0071","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0072","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.13862","article-title":"Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab","volume":"45","author":"Ungar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100271_bib0073","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.eclinm.2020.100271_bib0074","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213403","article-title":"Methotrexate and BAFF interaction prevents immunization against TNF inhibitors","volume":"77","author":"Bitoun","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0075","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ibd\/izx065","article-title":"Combination immunosuppression in IBD","volume":"24","author":"Bots","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0076","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MIB.0000000000000589","article-title":"Use of methotrexate in the treatment of inflammatory bowel diseases","volume":"22","author":"Herfarth","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.eclinm.2020.100271_bib0077","unstructured":"Ulcerative Colitis: Clinical trial endpoints guidance for industry. 2019: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-clinical-trial-endpoints-guidance-industry (Assessed Jan 10, 2020)."},{"key":"10.1016\/j.eclinm.2020.100271_bib0078","unstructured":"European Medicines Agency (EMA)Guideline on the development of new medicinal products for the treatment of ulcerative colitis. 2018: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_001026.jsp&mid=WC0b01ac0580032ec6 (Assessed Jan 10, 2020)."},{"key":"10.1016\/j.eclinm.2020.100271_bib0079","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020300158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020300158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:01:04Z","timestamp":1762887664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537020300158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":79,"alternative-id":["S2589537020300158"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100271","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100271"}}